NCT03021018View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

April 27, 2018

Study Completion Date

April 27, 2018

Conditions
Epilepsy
Interventions
DRUG

Brivaracetam

"* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/ml~* Route of Administration: intravenous"

DRUG

Lorazepam

"* Pharmaceutical Form: Solution for injection~* Route of Administration: intravenous"

Trial Locations (14)

14642

Ep0087 120, Rochester

27599

Ep0087 121, Chapel Hill

28204

Ep0087 105, Charlotte

32806

Ep0087 112, Orlando

35294

Ep0087 108, Birmingham

48201

Ep0087 107, Detroit

60611

Ep0087 115, Chicago

60612

Ep0087 113, Chicago

67214

Ep0087 119, Wichita

85724

Ep0087 117, Tucson

02478

Ep0087 116, Belmont

02215

Ep0087 106, Boston

03756

Ep0087 125, Lebanon

17033-2360

Ep0087 123, Hershey

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03021018 - A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting | Biotech Hunter | Biotech Hunter